Researchers say a combination of biomarkers may offer insights to build a noninvasive screening tool for pancreatic cancer as it related to new-onset diabetics.
PHILADELPHIA - Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.